Literature DB >> 28431489

Apathy in amyotrophic lateral sclerosis: insights from Dimensional Apathy Scale.

Gabriella Santangelo1,2, Mattia Siciliano1,3, Luigi Trojano1,4, Cinzia Femiano3, Maria Rosaria Monsurrò3, Gioacchino Tedeschi3, Francesca Trojsi3.   

Abstract

OBJECTIVES: Apathy is associated with cognitive decline and worse survival in amyotrophic lateral sclerosis (ALS); an accurate evaluation of this aspect is relevant in clinical settings. The aims of this study are to evaluate the prevalence of apathy in a large ALS sample, using published diagnostic criteria, and to explore the psychometric properties, the sensitivity and the specificity of the Dimensional Apathy Scale (DAS) as a screening tool for apathy.
METHODS: One hundred and thirty-one patients underwent clinical interview based on diagnostic criteria for apathy, DAS, Apathy Evaluation Scale, and assessment of depression, global cognitive functioning, and non-verbal intelligence.
RESULTS: According to diagnostic criteria, apathy occurred in 28.2% of the patients. The DAS showed high consistency, convergent, and discriminant validities. Apathetic and non-apathetic patients significantly differed on total DAS and executive and Behavioral/Cognitive Initiation subscales, indicating good criterion validity. Receiver operating characteristics analysis, considering diagnostic criteria for apathy as gold standard, revealed that a score of 26/27 was an optimal cut-off score for the identification of apathy.
CONCLUSIONS: The DAS is a valid screening tool for apathy and its aspects in ALS through limiting the impact of physical disability. Executive and behavioral/cognitive aspects of apathy, rather than emotional aspects, are more frequent in ALS.

Entities:  

Keywords:  ALS; Apathy; DAS; amyotrophic lateral sclerosis; dimensional apathy scale; non motor symptoms

Mesh:

Year:  2017        PMID: 28431489     DOI: 10.1080/21678421.2017.1313865

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  7 in total

1.  Apathy and its impact on patient outcome in amyotrophic lateral sclerosis.

Authors:  J Caga; S Hsieh; E Highton-Williamson; M C Zoing; E Ramsey; E Devenney; R M Ahmed; M C Kiernan
Journal:  J Neurol       Date:  2017-11-30       Impact factor: 4.849

2.  Assessment of apathy minimising the effect of motor dysfunctions in Parkinson's disease: a validation study of the dimensional apathy scale.

Authors:  Gabriella Santangelo; Alfonsina D'Iorio; Fausta Piscopo; Sofia Cuoco; Katia Longo; Marianna Amboni; Chiara Baiano; Domenico Tafuri; Maria Teresa Pellecchia; Paolo Barone; Carmine Vitale
Journal:  Qual Life Res       Date:  2017-04-07       Impact factor: 4.147

3.  Multidimensional Apathy: The Utility of the Dimensional Apathy Scale in Huntington's Disease.

Authors:  Kelly J Atkins; Sophie C Andrews; Trevor T-J Chong; Julie C Stout
Journal:  Mov Disord Clin Pract       Date:  2021-02-12

Review 4.  The Impact of Cognitive and Behavioral Symptoms on ALS Patients and Their Caregivers.

Authors:  Jashelle Caga; Sharpley Hsieh; Patricia Lillo; Kaitlin Dudley; Eneida Mioshi
Journal:  Front Neurol       Date:  2019-03-11       Impact factor: 4.003

5.  The stability of multidimensional subclinical apathy during a pandemic and its relations to psycho-behavioral factors.

Authors:  Giulia Lafond-Brina; Anne Bonnefond
Journal:  Sci Rep       Date:  2022-02-21       Impact factor: 4.379

6.  Heightened effort discounting is a common feature of both apathy and fatigue.

Authors:  Mindaugas Jurgelis; Wei Binh Chong; Kelly J Atkins; Patrick S Cooper; James P Coxon; Trevor T-J Chong
Journal:  Sci Rep       Date:  2021-11-15       Impact factor: 4.379

7.  Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch.

Authors:  Angela Genge; Benjamin Rix Brooks; Björn Oskarsson; Alexander Kalin; Ming Ji; Stephen Apple; Laura Bower
Journal:  Drugs R D       Date:  2022-06-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.